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Abstract
Background: No studies have been reported on the efficacy and safety of long-term (≥12 months) use of topical
tacrolimus for refractory ocular surface inflammation in pediatric patients.
Methods: Medical records of pediatric patients who were prescribed topical 0.02% tacrolimus ointment for
refractory ocular surface inflammation between January of 2010 and March of 2018 were reviewed retrospectively.
Changes in ocular surface signs during slit-lamp examination, clinical symptoms and concurrent steroid use were
graded with a scoring system. The presence of side effects was also assessed. The changes in disease severity and
patient symptoms were compared between baseline and after the treatment.
Results: Among 72 patients (55% males, mean age 10.8 ± 3.9 years, range 3 to 17 years), 25 patients (48% males,
mean age 11.4 ± 3.9 years) fully recovered, resulting in discontinuance of the ointment treatment before 12 months.
Six patients experienced intolerable burning sensation, which required treatment cessation. Cessation days of those
who quit were 1,5,14,20,26, and 35 days. Seven patients were lost during follow-up. Thirty-four patients (56% males,
mean age 11.2 ± 4.2 years, range 3 to 17 years) were treated with tacrolimus ointment for over 12 months (average
23.1 ± 19.1 months, range 12 to 98 months). During the follow-up period, all patients showed improved clinical
signs and symptoms, and no adverse reaction was noted.
Conclusions: Long-term maintenance of topical tacrolimus 0.02% ointment is safe and effective in improving
refractory ocular surface inflammation in pediatric patients.
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Background
The ocular surface inflammation management requires
intense immunosuppression [1]. T helper 2 cells play a
vital role in the pathogenesis of vernal keratoconjunctivi-
tis (VKC) [2]. In atopic keratoconjunctivitis (AKC), both
T helper 1 and 2 cytokines are expressed in the irritated
conjunctiva [3]. Chronic ocular Graft-versus-host disease
(GVHD) occurs by reactive T cell [4]. In ocular
cicatricial pemphigoid (OCP), T cells are responsible for
producing conjunctival scarring [1]. Stevens–Johnson
syndrome (SJS) lesions are produced by the migration of
cytotoxic T lymphocytes [5]. The pathogenesis of phlyc-
tenular keratoconjunctivitis (PKC) is delayed-type hyper-
sensitivity [6].
Topical steroids are the main treatment for these
diseases. However, prolonged steroid use can poten-
tially cause severe adverse reactions, including
steroid-induced glaucoma (SIG), posterior subcapsular
cataract, and secondary infection [7]. Pediatric pa-
tients tend to show a more severe response to topical
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steroids compared to adults [7, 8]. In one study in-
volving 1259 children with glaucoma, 4.7% were cases
of SIG. Of these patients, 87% had been prescribed
with topical steroids for VKC [7].
To overcome the limitations of steroids, topical immu-
nosuppressants have been used as an alternative. Tacro-
limus is a nonsteroidal macrolide immunosuppressant
isolated from Streptomyces tsukubaensis and is known to
be 30 ~ 100 times more powerful than cyclosporine [9].
The mechanism by which tacrolimus suppresses inflam-
matory reactions is not clear. So far, it has been discov-
ered that tacrolimus attaches to FK506-binding proteins
within T lymphocytes and suppresses calcineurin activity
[10]. Subsequent inhibition of T lymphocytes results in
the inhibition of release of inflammatory cytokines [1],
including IL-2 from T lymphocytes [11]. The application
of topical tacrolimus is effective in treating various T-
cell-mediated ocular diseases [1].
Many studies have described satisfactory results with
topical tacrolimus on various ocular surface inflamma-
tion [1, 12, 13]. However, no studies till date have inves-
tigated the safety of long-term (≥12 months) use of
topical tacrolimus in pediatric patients for treating ocu-
lar surface inflammation.
The goal of this paper was to evaluate the efficacy and
safety of long-term treatment using topical 0.02% tacro-
limus ointment in pediatric patients with ocular surface
inflammation refractory to conventional therapy.
Methods
We retrospectively reviewed the medical records of
72 consecutive patients diagnosed with ocular surface
inflammation such as ocular GVHD, VKC, AKC,
OCP, SJS, and PKC under 18 years old. The patients
had been prescribed with topical 0.02% tacrolimus
ointment for refractory ocular surface inflammation
between January of 2010 and March of 2018 at the
Department of Ophthalmology, Severance Hospital,
Yonsei University, Seoul, Republic of Korea from
January 2010 to March 2018.
This study was conducted at the Department of Oph-
thalmology, Severance Hospital, Yonsei University,
Seoul, Republic of Korea. The study protocol was ap-
proved by the Institutional Review Board of Yonsei Uni-
versity, Seoul, Republic of Korea (IRB number: 4–2019-
1315), and it adhered to the tenets of the Declaration of
Helsinki. The written informed consent was waived be-
cause of the retrospective design and the use of deidenti-
fied patient data.
We defined those cases that showed persistence of
symptoms and signs despite receiving a topical 0.12 or
1% prednisone acetate or use of systemic steroids treat-
ment for more than 3months, cases in which there was
a relapse after tapering or withdrawal of steroids, and
cases in which steroid-related complications developed
as “refractory to conventional treatment”. The “refrac-
tory to conventional treatment” patients were prescribed
with topical 0.02% tacrolimus ointment as an adjunct
immunosuppressive therapy in addition to previous ster-
oid treatments [12].
The exclusion criteria were as follows: patients with
history of tacrolimus eye drops, ocular bacterial infec-
tion, ocular herpetic infection, ocular chemical injury,
previous ocular trauma, and contact lens wearer. The
following information at the beginning and each follow-
up (every month up to 3 months, and every 3 months
after that) was obtained from a retrospective chart re-
view: demographic data including diagnosis, systemic
disease, clinical features, uncorrected visual acuity
(UCVA), best corrected visual acuity (BCVA), intraocu-
lar pressure (IOP), disease severity (symptom and sign
score), steroid score, and presence of any adverse reac-
tion. Disease severity was classified as absent, mild, mod-
erate, or severe according to a grading system out of
four points (0 to 3 points) based on symptoms and signs
(Table 1) [14]. Clinical outcomes were assessed using
the same grading system. The primary measure of treat-
ment efficacy was a decrease the composite score of
symptoms and signs. The changes in the composite
score of symptoms and signs were compared between
baseline and after the treatment. The slit-lamp examina-
tions and a questionnaire to subject symptoms were
conducted by a single clinician (KYS) for consistency.
Pediatric patients usually do not allow good slit lamp
examination. In case of poor cooperation of the patients,
slit lamp examination was performed using portable slit
lamp.
The use of steroid was categorized and scored on a
scale of 0 to 4. The score of 0 indicates no steroid neces-
sary; 1 indicates the use of 0.1% topical fluorometholone
(Ocumetholone®; Samil Pharmaceutical Co., Ltd., Seoul,
Republic of Korea); 2 indicates the use of 0.12% topical
prednisone acetate (Optilon®; Chong Kun Dang Pharma-
ceutical Co., Seoul, Republic of Korea); 3 indicates the
use of 1% topical prednisone acetate (Predforte®; Aller-
gan Inc., Irvine, CA, USA); and 4 indicates the use of
systemic steroids with or without concurrent topical
prednisone acetate of 1% [12, 15].
The commercial tacrolimus ointment (Protopic® oint-
ment 0.03%; Astellas Pharma, Tokyo, Japan), which has
been used to treat dermatologic disorders, is extremely
viscous and inappropriate for direct application into the
conjunctival sac [4, 12]. Hence, we made a preparation
of 0.02% tacrolimus ointment by diluting the 0.03% ta-
crolimus ointment ratio of 2:1 by volume with a less vis-
cous ophthalmic ointment (Duratears®; Alcon
Laboratories, Inc., Fort Worth, Texas, USA). The Dura-
tears® ointment is composed of 30 mg anhydros liquid
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lanolin per gram of mineral oil base [16]. The patients
were instructed to put the topical 0.02% tacrolimus oint-
ment about the size of a rice grain into the conjunctival
sac twice a day [4, 12].
All continuous data are expressed as mean ± standard
deviation (SD) while categorical data were presented as
number and percentage of the total population. Statis-
tical analyses were performed with the SPSS statistical
software package (version 20.0; SPSS Inc., Chicago, Illi-
nois, USA). A p-value less than 0.05 was considered sta-
tistically significant.
Results
There were 72 patients (55% males, mean age 10.8 ± 3.9
years, range 3 to 17 years) who were prescribed topical
0.02% tacrolimus ointment for refractory ocular surface
inflammation between January of 2010 and March of
2018. All patients had bilateral ocular involvement.
Seven patients were lost during follow-up. Six patients
(17% males, mean age 10.3 ± 3.1 years, range 6 to 14
years) experienced painful burning sensation and with-
drew from the tacrolimus treatment. The number of
days before the cessation of treatment due to severe
burning sensation was 1, 5, 14, 20, 26, and 35 days
(Fig. 1). Twenty-five patients (48% males, mean age
11.4 ± 3.9 years, range 4 to 16 years) fully recovered,
resulting in discontinuation of the tacrolimus ointment
before 12 months. The mean duration of using the tacro-
limus ointment in this group was 3.61 ± 2.45months
(range 1 to 8 months). Thirty-four patients (56% males,
Table 1 Grading system of disease severity
Fig. 1 The flowchart of pediatric patients who were treated with the topical 0.02% tacrolimus ointment for refractory ocular surface inflammation
Koh et al. BMC Ophthalmology          (2021) 21:247 Page 3 of 7
mean age 11.2 ± 4.2 years, range 3 to 17 years) were
treated with tacrolimus ointment for 12 months or more
(mean follow-up period 23.12 ± 19.07 months, range 12
to 98months).
There were no corneal deposits, subepithelial keratitis,
ocular surface staining, IOP elevation, infections, or
other unfavorable influences associated with the use of
topical tacrolimus ointment. No side effects other than
burning sensation were identified during the follow-up
period.
The distribution of diagnosis of 65 patients (seven pa-
tients lost to follow-up were excluded) is as follows: The
most common diagnosis was AKC (46%), followed by
VKC (35%), GVHD (15%) and PKC (3%). SJS and OCP
each accounted for 1%. The mean duration of using the
tacrolimus ointment in AKC group (54% males, mean
age 10.6 ± 3.8 years, range 4 to 17 years) was 8.89 ± 5.14
months (range 1 to 21months). Three of 34 patients ex-
perienced painful burning sensation which required
treatment cessation. The mean duration of using the ta-
crolimus ointment in VKC group (60% males, mean age
11.5 ± 3.6 years, range 6 to 17 years) was 10.25 ± 3.45
months (range 1 to 20months). Three of 32 patients ex-
perienced painful burning sensation and the treatment
was withheld. The mean duration of using the tacroli-
mus ointment in ocular GVHD group (56% males, mean
age 9.24 ± 5.5 years, range 3 to 16 years) was 25.01 ±
14.35 months (range 13 to 55 months). All of PKC (67%
males, mean age 13.6 ± 1.5 years, range 12 to 15 years),
OCP (female, age 11 years), and SJS (male, age 14 years)
patients used tacrolimus ointment for more than 12 con-
secutive months without reporting any side effects.
Comparisons of ocular examination results between
before and after the treatment of 34 patients with a
follow-up period of 12 months or longer showed no sig-
nificant difference in the UCVA, BCVA, and mean IOP
(Table 2). Disease severity was calculated by the sum of
symptom and sign scores (Table 1). The composite score
of symptoms and signs was computed at the beginning
and each follow-up. The mean composite sign score at
initial visit was 9.44 ± 2.11 and dropped to 2.85 ± 1.37 at
12 months (P < .001) (Fig. 2). The mean composite
symptom score at initial visit was 7.35 ± 1.85 and
dropped to 2.18 ± 1.08 at 12 months (P < .001) (Fig. 2).
The changes in mean scores for the symptoms and signs
during follow-up are demonstrated in Fig. 2. After 1
month of treatment, significant improvement in symp-
toms and signs was noted (Fig. 2). The total sign score
(range, 0 to 12) significantly decreased 1 month after ini-
tiation of topical tacrolimus ointment in all disease
groups (Fig. 3a). The total symptom score (range, 0 to
12) also showed a significant decrease from baseline 4
weeks after initiation of topical tacrolimus ointment in
all disease groups (Fig. 3b).
During the follow-up, the percentage of eyes receiving
adjunctive topical steroid treatment decreased to 82% at
2 months and 47% at 6 months. The percentage of eyes
with adjunctive 1% prednisone was 41, 29, and 6% at 1,
2, and 6 months, respectively. The percentage of eyes
with adjunctive 0.1% fluorometholone eye drops was 32,
29, and 24% at 1, 2, and 6months, respectively. More
than half of the total patients were treated with tacroli-
mus alone, successfully weaned off topical steroids at 6
months. (Fig. 4). The steroid score improved signifi-
cantly from 3.32 ± 0.84 at baseline to 0.58 ± 0.65 at the
final follow-up (Table 2).
Discussion
The current study investigated the long-term safety of
topical tacrolimus treatment in pediatric patients with
ocular surface inflammation that was refractory to con-
ventional treatment. To our knowledge, this study was
conducted with the longest observation period for evalu-
ating the safety and efficacy of topical tacrolimus in
pediatric patients.
The largest study till date on topical tacrolimus use in
pediatric patients reported its use in 45 patients (mean
age: 8.23 ± 2.7 years) of VKC with an average follow-up
of eight months. In this study, 89% of patients showed
significant improvement and no side effects were re-
ported except that one patient developed subepithelial
keratitis [17]. Our study included 34 patients (mean age:
Table 2 Before and after treatment comparison of parameters associated with therapeutic effects
Variable Before treatment Final follow-up P-value
UCVA (logMAR, mean ± SD) 0.44 ± 0.19 0.39 ± 0.13 0.352a
BCVA (logMAR, mean ± SD) 0.22 ± 0.31 0.18 ± 0.30 0.199a
IOP, mmHg (mean ± SD) 14.82 ± 3.63 15.26 ± 2.57 0.419a
Symptom Score 7.35 ± 1.85 1.23 ± 0.95 0.001b*
Sign Score 9.44 ± 2.11 1.71 ± 1.06 0.001b*
Steroid Score 3.32 ± 0.84 0.58 ± 0.65 0.001b*
UCVA uncorrected visual acuity, BCVA best corrected visual acuity, logMAR logarithm of the minimum angle of resolution, SD standard deviation, IOP
intraocular pressure
aPaired-t test; bWilcoxon signed rank test
*P < 0.05 was considered statistically significant
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11.2 ± 4.2 years) with follow-up period of 12 months or
longer. The average follow-up period reached 23.12 ±
19.07 (range, 12 to 98) months. In addition to VKC, our
study included various ocular surface inflammation such
as ocular GVHD, OCP, SJS, AKC, and PKC. The results
of our analyses showed that majority of patients toler-
ated the treatment, showed improved symptoms and
clinical signs, and required less concurrent steroid ther-
apy. Over 12 months of follow-up, no adverse reaction
was noted.
In our study, patients were initially prescribed 0.02%
tacrolimus ointment in combination with topical ste-
roids during the active phase because topical tacrolimus
requires several weeks to reach the treatment concentra-
tion in eyes. On the other hand, topical steroids are fast-
acting and promptly relieve symptoms [18–20]. There-
fore, topical steroids help resolve inflammation in the
cornea and conjunctiva immediately until tacrolimus be-
comes effective.
The major side effects of topical tacrolimus are eye ir-
ritation, blurring, itching, chemosis, transient burning
sensation, conjunctival hyperemia, and conjunctival che-
mosis [5]. Burning sensation, which was the reason be-
hind treatment cessation in our study population, has
been documented in previously published reports using
higher concentrations (0.01%) but not in those using
lower concentrations (0.005%). Hence, it is possible that
this side effect is dependent on the drug concentration
[5, 21, 22]. In terms of adverse effects, renal toxicity,
hyperglycemia, and hypertension have been reported
[23]. However, because of the limited amount of tacroli-
mus used during topical treatment, the risk of these ad-
verse effects is negligible. A study that investigated the
blood concentration profile of tacrolimus following top-
ical application, its systemic exposure was reported to be
minimal and temporary [24]. There have also been re-
ports of complications such as blood dyscrasias, malig-
nancies and outbreaks of infection including herpes
simplex as well as organ damage with the use of tacroli-
mus. Such complications are thought occur more fre-
quently in children, but no systemic complications were
noted in our study. to be greater in children. A possible
local adverse effect of topical tacrolimus is an increased
predisposition to infections [20]. A study has shown that
its long-term usage increases the risk of corneal infec-
tions [22]. The prevalence of corneal infections in a large
cohort of patients treated with topical tacrolimus was
0.35% [5]. However, no ocular complications were ob-
served during our study.
Fig. 2 Comparison of overall symptom and sign score during the
follow-up period. Both scores decrease during the treatment period
Fig. 3 Comparison of each sign scores (a) and symptom scores (b) among disease groups during the follow-up period. It shows the changes in
both scores during the treatment period for each disease
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The study has several limitations. Most patients (80%)
were VKC and AKC patients. And because of that, the
number of patients who finally maintained treatment for
more than 12 months was relatively small. The clinical
signs and severity were evaluated by the representative
signs common in six disease groups such as conjunctival
fibrosis, conjunctival hyperemia, limbal inflammation,
and punctate keratopathy. However, these parameters
are not enough to evaluate the severity of AKC or VKC.
In particular, the Shield’s ulcer and palpebral conjunc-
tival involvement features are essential for evaluating the
severity of VKC. This study is not only about AKC or
VKC, but it includes six disease groups. So, we could
not include the signs that appear only in certain diseases.
Further studies with a larger number of subjects and a
longer period of follow-up and divided by each ocular
surface inflammation would be necessary to verify the
safety of topical tacrolimus in pediatric patients with re-
fractory ocular surface inflammation. Despite these limi-
tations, we believe that our long-term observation
supported tacrolimus as an effective and safe treatment
option in pediatric patients with refractory ocular sur-
face inflammation.
Conclusions
Long-term treatment of topical tacrolimus 0.02% oint-
ment is safe and effective in refractory ocular surface in-
flammation in pediatric patients.
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